{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:37:14Z","timestamp":1793266634587,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2023-03-36"],"award-info":[{"award-number":["320.6750.2023-03-36"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jpet.2026.104997","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:39:11Z","timestamp":1785512351000},"page":"104997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptide\u2013drug conjugates in breast cancer therapy: Emerging targets, translational challenges, and optimization strategies"],"prefix":"10.1016","volume":"393","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"21","key":"10.1016\/j.jpet.2026.104997_bib2","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","article-title":"Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.jpet.2026.104997_bib3","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","article-title":"Molecular classification of hormone receptor-positive HER2-negative breast cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.jpet.2026.104997_bib4","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.ccell.2025.06.019","article-title":"A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture","volume":"43","author":"Meyer","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jpet.2026.104997_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jpet.2026.104997_bib6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s43018-021-00229-1","article-title":"Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment","volume":"2","author":"Pasha","year":"2021","journal-title":"Nat Cancer"},{"issue":"12","key":"10.1016\/j.jpet.2026.104997_bib7","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.jpet.2026.104997_bib8","first-page":"426","article-title":"T-DXd is effective after T-DM1","volume":"20","author":"Sidaway","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30918-5","article-title":"T-DM1 for residual, invasive, HER2-positive breast cancer","volume":"20","author":"Burki","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/bioengineering12050481","article-title":"Peptide-drug conjugates as next-generation therapeutics: exploring the potential and clinical progress","volume":"12","author":"Jadhav","year":"2025","journal-title":"Bioengineering (Basel)"},{"issue":"9","key":"10.1016\/j.jpet.2026.104997_bib12","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.apsb.2023.02.013","article-title":"Research advances in peptide\u2012drug conjugates","volume":"13","author":"Gong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jpet.2026.104997_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117204","article-title":"Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy","volume":"284","author":"He","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","article-title":"Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy","volume":"11","author":"Wu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"34","key":"10.1016\/j.jpet.2026.104997_bib16","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41388-022-02409-4","article-title":"Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin \u03b1v\u03b23","volume":"41","author":"Liu","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.jpet.2026.104997_bib17","article-title":"Blockage of \u03b1v\u03b23 integrin in 3D culture of triple-negative breast cancer and endothelial cells inhibits migration and discourages endothelial-to-mesenchymal plasticity","volume":"38","author":"Casali","year":"2024","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.jpet.2026.104997_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106694","article-title":"The challenges and opportunities of \u03b1v\u03b23-based therapeutics in cancer: from bench to clinical trials","volume":"189","author":"Gu","year":"2023","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12959-023-00463-w","article-title":"Structure, signal transduction, activation, and inhibition of integrin \u03b1IIb\u03b23","volume":"21","author":"Xin","year":"2023","journal-title":"Thromb J"},{"key":"10.1016\/j.jpet.2026.104997_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117056","article-title":"Synthesis and evaluation of a novel BODIPY fluorescent probe targeting integrin \u03b1v\u03b23 for cancer diagnosis","volume":"282","author":"Rong","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jpet.2026.104997_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1358393","article-title":"Neutrophil elastase as a versatile cleavage enzyme for activation of \u03b1v\u03b23 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment","volume":"15","author":"Rebstock","year":"2024","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.jpet.2026.104997_bib22","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.7150\/thno.20242","article-title":"A nanosystem of amphiphilic oligopeptide-drug conjugate actualizing both \u03b1v\u03b23 targeting and reduction-triggered release for maytansinoid","volume":"7","author":"Liang","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jpet.2026.104997_bib23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jconrel.2024.07.074","article-title":"Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying peptide-drug conjugate","volume":"375","author":"Kim","year":"2024","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.jpet.2026.104997_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202306676","article-title":"Inhibiting endothelial cell-mediated T lymphocyte apoptosis with integrin-targeting peptide-drug conjugate filaments for chemoimmunotherapy of triple-negative breast cancer","volume":"36","author":"Cai","year":"2024","journal-title":"Adv Mater"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10555-024-10237-z","article-title":"Neuropeptide Y in cancer-biological functions and potential clinical implications","volume":"44","author":"Sigorski","year":"2025","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"10.1016\/j.jpet.2026.104997_bib26","first-page":"4636","article-title":"Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets","volume":"61","author":"Reubi","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jpet.2026.104997_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3892\/ol.2014.2721","article-title":"NPY1R is a novel peripheral blood marker predictive of metastasis and prognosis in breast cancer patients","volume":"9","author":"Liu","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jpet.2026.104997_bib28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jconrel.2015.04.037","article-title":"A cleavable cytolysin-neuropeptide Y bioconjugate enables specific drug delivery and demonstrates intracellular mode of action","volume":"209","author":"Ahrens","year":"2015","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.jpet.2026.104997_bib29","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1021\/acs.jmedchem.6b00043","article-title":"Double methotrexate-modified neuropeptide Y analogues express increased toxicity and overcome drug resistance in breast cancer cells","volume":"59","author":"B\u00f6hme","year":"2016","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cmdc.201402514","article-title":"Controlling toxicity of peptide-drug conjugates by different chemical linker structures","volume":"10","author":"B\u00f6hme","year":"2015","journal-title":"ChemMedChem"},{"issue":"8","key":"10.1016\/j.jpet.2026.104997_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41419-024-07016-7","article-title":"Effect of Sortilin1 on promoting angiogenesis and systemic metastasis in hepatocellular carcinoma via the Notch signaling pathway and CD133","volume":"15","author":"Ahn","year":"2024","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.jpet.2026.104997_bib32","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.18632\/oncotarget.3401","article-title":"Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion","volume":"6","author":"Roselli","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpet.2026.104997_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760787","article-title":"New peptide-drug conjugates for precise targeting of SORT1-mediated vasculogenic mimicry in the tumor microenvironment of TNBC-derived MDA-MB-231 breast and ovarian ES-2 clear cell carcinoma cells","volume":"11","author":"Charfi","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/1878-0261.13106","article-title":"Sortilin-related receptor is a druggable therapeutic target in breast cancer","volume":"16","author":"Al-Akhrass","year":"2022","journal-title":"Mol Oncol"},{"issue":"10","key":"10.1016\/j.jpet.2026.104997_bib35","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1111\/cas.15086","article-title":"TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer","volume":"112","author":"Demeule","year":"2021","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.jpet.2026.104997_bib36","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/pharmaceutics14091910","article-title":"The TH1902 docetaxel peptide-drug conjugate inhibits xenografts growth of human SORT1-positive ovarian and triple-negative breast cancer stem-like cells","volume":"14","author":"Demeule","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpet.2026.104997_bib37","article-title":"Sudocetaxel zendusortide (TH1902) triggers the cGAS\/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing","volume":"15","author":"Demeule","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jpet.2026.104997_bib38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer \u2013 an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104997_bib39","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-06-2480","article-title":"A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jpet.2026.104997_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3602","article-title":"Peptide-drug conjugate designated for targeted delivery to HER2-expressing cancer cells","volume":"30","author":"Sharma","year":"2024","journal-title":"J Pept Sci"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1535-7163.MCT-12-0357","article-title":"HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo","volume":"12","author":"Kawamoto","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.jpet.2026.104997_bib42","article-title":"Precise HER2 protein degradation via peptide-conjugated photodynamic therapy for enhanced breast cancer immunotherapy","volume":"12","author":"Guo","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/cells8050497","article-title":"Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin","volume":"8","author":"Sharma","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188664","article-title":"Keratin 1 as a cell-surface receptor in cancer","volume":"1877","author":"Ogunnigbagbe","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10.1016\/j.jpet.2026.104997_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00428-012-1289-9","article-title":"Keratin expression in breast cancers","volume":"461","author":"Shao","year":"2012","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.jpet.2026.104997_bib46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/acs.molpharmaceut.6b00652","article-title":"Breast cancer targeting peptide binds keratin 1: a new molecular marker for targeted drug delivery to breast cancer","volume":"14","author":"Soudy","year":"2017","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.jpet.2026.104997_bib47","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1021\/acs.molpharmaceut.3c00189","article-title":"Peptide-drug conjugate targeting keratin 1 inhibits triple-negative breast cancer in mice","volume":"20","author":"Ziaei","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jpet.2026.104997_bib48","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3389\/fcell.2020.00662","article-title":"Neuropilins, as relevant oncology target: their role in the tumoral microenvironment","volume":"8","author":"Dumond","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e27368","article-title":"Bioinformatics analysis and clinical significance of NRP-1 in triple-negative breast cancer","volume":"10","author":"Ma","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.jpet.2026.104997_bib50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jsb.2013.02.006","article-title":"Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor","volume":"182","author":"Zanuy Gomara","year":"2013","journal-title":"J Struct Biol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104997_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jphotobiol.2009.04.008","article-title":"Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo","volume":"96","author":"Thomas","year":"2009","journal-title":"J Photochem Photobiol B"},{"issue":"11","key":"10.1016\/j.jpet.2026.104997_bib52","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1530\/ERC-20-0442","article-title":"New drug delivery strategies targeting the GnRH receptor in breast and other cancers","volume":"28","author":"Ghaly","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib53","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.1038\/s41598-020-64979-1","article-title":"LHRH-conjugated drugs as targeted therapeutic agents for the specific targeting and localized treatment of triple negative breast cancer","volume":"10","author":"Obayemi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2026.104997_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104739","article-title":"Targeting GRP receptor: design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin","volume":"109","author":"Palmioli","year":"2021","journal-title":"Bioorg Chem"},{"issue":"18","key":"10.1016\/j.jpet.2026.104997_bib55","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3390\/cells14181482","article-title":"Targeting the CXCR4\/CXCL12 axis to overcome drug resistance in triple-negative breast cancer","volume":"14","author":"Singh","year":"2025","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.jpet.2026.104997_bib56","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1166\/jbn.2021.3104","article-title":"Trojan-like peptide drug conjugate design and construction for application in treatment of triple-negative breast cancer","volume":"17","author":"Xiao","year":"2021","journal-title":"J Biomed Nanotechnol"},{"issue":"12","key":"10.1016\/j.jpet.2026.104997_bib57","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib58","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.3390\/ijms24043400","article-title":"Targeting the gastrin-releasing peptide receptor (GRP-R) in cancer therapy: development of bombesin-based peptide-drug conjugates","volume":"24","author":"Gomena","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jpet.2026.104997_bib59","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.apsb.2023.03.024","article-title":"Self-assembly of CXCR4 antagonist peptide-docetaxel conjugates for breast tumor multi-organ metastasis inhibition","volume":"13","author":"Li","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"10.1016\/j.jpet.2026.104997_bib60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","article-title":"Peptide-drug conjugate-based novel molecular drug delivery system in cancer","volume":"42","author":"Zhu","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jpet.2026.104997_bib61","article-title":"Trends in the research and development of peptide drug conjugates: artificial intelligence aided design","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104997_bib62","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.xphs.2024.04.023","article-title":"\u201cNegative\u201d impact: the role of payload charge in the physicochemical stability of auristatin antibody-drug conjugates","volume":"113","author":"Johann","year":"2024","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.jpet.2026.104997_bib63","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.xphs.2018.03.022","article-title":"Biophysical properties and heating-induced aggregation of lysine-conjugated antibody-drug conjugates","volume":"107","author":"Gandhi","year":"2018","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?","volume":"23","author":"Wang","year":"2025","journal-title":"J Nanobiotechnology"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib65","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-019-04530-1","article-title":"Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors","volume":"47","author":"Liu","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib66","article-title":"The safety and efficacy of the repeated PRRT with [90Y]Y\/[177Lu]Lu-DOTATATE in patients with NET","volume":"2021","author":"Zemczak","year":"2021","journal-title":"Int J Endocrinol"},{"issue":"13","key":"10.1016\/j.jpet.2026.104997_bib67","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","article-title":"[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients","volume":"47","author":"Pauwels","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.jpet.2026.104997_bib68","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jpet.2026.104997_bib69","doi-asserted-by":"crossref","first-page":"19216","DOI":"10.1021\/acs.jmedchem.4c01652","article-title":"Advancing cancer immunotherapy through engineering new PD-L1 degraders: a comprehensive study from small molecules to PD-L1-specific peptide-drug conjugates","volume":"67","author":"Zeng","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2026.104997_bib70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejmech.2018.05.039","article-title":"Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates","volume":"155","author":"Zheng","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"19","key":"10.1016\/j.jpet.2026.104997_bib71","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.3390\/ijms20194763","article-title":"Improved in vivo anti-tumor and anti-metastatic effect of GnRH-III-daunorubicin analogs on colorectal and breast carcinoma bearing mice","volume":"20","author":"Ran\u0111elovi\u0107","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3762\/bjoc.15.11","article-title":"Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells","volume":"15","author":"Kufka","year":"2019","journal-title":"Beilstein J Org Chem"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.108672","article-title":"Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition","volume":"35","author":"Cao","year":"2024","journal-title":"Chinese Chemical Letters"},{"issue":"2","key":"10.1016\/j.jpet.2026.104997_bib74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/acsptsci.3c00269","article-title":"Peptide-drug conjugates: design, chemistry, and drug delivery system as a novel cancer theranostic","volume":"7","author":"Rizvi","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"15","key":"10.1016\/j.jpet.2026.104997_bib75","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2016.34.15_suppl.2004","article-title":"ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer","volume":"34","author":"Kumthekar","year":"2016","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.jpet.2026.104997_bib76","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1200\/JCO-25-00559","article-title":"First-in-human, phase I\/II dose escalation and expansion study of zelenectide pevedotin in patients with advanced solid tumors: results from monotherapy dose escalation","volume":"43","author":"Baldini","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16\u2013Suppl","key":"10.1016\/j.jpet.2026.104997_bib77","article-title":"An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8_Suppl","key":"10.1016\/j.jpet.2026.104997_bib78","article-title":"Abstract CT063: an EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: results from a phase 1\/2 study","volume":"86","author":"Bashir","year":"2026","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(25)00762-4","article-title":"[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study","volume":"27","author":"Priv\u00e9","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jpet.2026.104997_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116119","article-title":"Peptide-drug conjugates: a new paradigm for targeted cancer therapy","volume":"265","author":"Wang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib81","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/ijms24010829","article-title":"Peptide drug conjugates and their role in cancer therapy","volume":"24","author":"Heh","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib82","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/pharmaceutics17040397","article-title":"Barriers and strategies for oral peptide and protein therapeutics delivery: update on clinical advances","volume":"17","author":"Baral","year":"2025","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jpet.2026.104997_bib83","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/med.22046","article-title":"Engineering peptide drug therapeutics through chemical conjugation and implication in clinics","volume":"44","author":"Rizvi","year":"2024","journal-title":"Med Res Rev"},{"issue":"2","key":"10.1016\/j.jpet.2026.104997_bib84","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/IGC.0000000000000044","article-title":"Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)","volume":"24","author":"Emons","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jpet.2026.104997_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107137","article-title":"Therapeutic stapled peptides: efficacy and molecular targets","volume":"203","author":"Li","year":"2024","journal-title":"Pharmacol Res"},{"issue":"18","key":"10.1016\/j.jpet.2026.104997_bib86","doi-asserted-by":"crossref","first-page":"12002","DOI":"10.1021\/acs.jmedchem.2c00539","article-title":"Discovery of cyclic peptide inhibitors targeting PD-L1 for cancer immunotherapy","volume":"65","author":"Fetse","year":"2022","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.jpet.2026.104997_bib87","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.3390\/cancers13153788","article-title":"Cyclic derivatives of the chemerin C-terminus as metabolically stable agonists at the chemokine-like receptor 1 for cancer treatment","volume":"13","author":"Fischer","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202113857","article-title":"Peptide-bismuth bicycles: in situ access to stable constrained peptides with superior bioactivity","volume":"61","author":"Voss","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"10.1016\/j.jpet.2026.104997_bib89","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib90","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/bip.20902","article-title":"Enantio- and diastereoselective syntheses of cyclic Calpha-tetrasubstituted alpha-amino acids and their use to induce stable conformations in short peptides","volume":"90","author":"Maity","year":"2008","journal-title":"Biopolymers"},{"issue":"9","key":"10.1016\/j.jpet.2026.104997_bib91","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/1389557516666160322152457","article-title":"N-methylated \u03b1-amino acids and peptides: synthesis and biological activity","volume":"16","author":"Di Gioia","year":"2016","journal-title":"Mini Rev Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib92","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1742-7843.2007.00008.x","article-title":"Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue","volume":"100","author":"Ferdinandi","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"28","key":"10.1016\/j.jpet.2026.104997_bib93","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2174\/138161210793292555","article-title":"Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization","volume":"16","author":"Gentilucci","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jpet.2026.104997_bib94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijbiomac.2021.07.080","article-title":"The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy","volume":"187","author":"Tao","year":"2021","journal-title":"Int J Biol Macromol"},{"issue":"13","key":"10.1016\/j.jpet.2026.104997_bib95","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1021\/acs.jmedchem.4c00511","article-title":"Development of peptide paratope mimics derived from the anti-ROR1 antibody and long-acting peptide-drug conjugates for targeted cancer therapy","volume":"67","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.jpet.2026.104997_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201804452","article-title":"Conjugate of doxorubicin to albumin-binding peptide outperforms aldoxorubicin","volume":"15","author":"Yousefpour","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.jpet.2026.104997_bib97","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2022.02.026","article-title":"Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer","volume":"344","author":"Cho","year":"2022","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.jpet.2026.104997_bib98","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","article-title":"The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics","volume":"97","author":"Fishburn","year":"2008","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.104997_bib99","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijpharm.2005.06.007","article-title":"Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids","volume":"300","author":"Gregoriadis","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jpet.2026.104997_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121985","article-title":"An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug","volume":"294","author":"Ozer","year":"2023","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib101","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/bc900070r","article-title":"Studies of poly(ethylene glycol) modification of HM-3 polypeptides","volume":"20","author":"Zhou","year":"2009","journal-title":"Bioconjug Chem"},{"issue":"4","key":"10.1016\/j.jpet.2026.104997_bib102","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3390\/ijms12042650","article-title":"In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG)","volume":"12","author":"Liu","year":"2011","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib103","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","article-title":"Lipid-drug conjugate for enhancing drug delivery","volume":"14","author":"Irby","year":"2017","journal-title":"Mol Pharm"},{"issue":"58","key":"10.1016\/j.jpet.2026.104997_bib104","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1002\/chem.201703093","article-title":"Multivalency increases the binding strength of RGD peptidomimetic-paclitaxel conjugates to integrin \u03b1V \u03b23","volume":"23","author":"Raposo Moreira Dias","year":"2017","journal-title":"Chemistry"},{"issue":"12","key":"10.1016\/j.jpet.2026.104997_bib105","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/chem.201905437","article-title":"Synthesis and biological characterization of monomeric and tetrameric RGD-cryptophycin conjugates","volume":"26","author":"Borb\u00e9ly","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.jpet.2026.104997_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113935","article-title":"A novel ICG-labeled cyclic TMTP1 peptide dimer for sensitive tumor imaging and enhanced photothermal therapy in vivo","volume":"227","author":"Wang","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib107","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.3390\/ijms24054590","article-title":"A novel homodimer peptide-drug conjugate improves the efficacy of HER2-positive breast cancer therapy","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"27","key":"10.1016\/j.jpet.2026.104997_bib108","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1039\/C5OB00497G","article-title":"Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery","volume":"13","author":"Bianchi","year":"2015","journal-title":"Org Biomol Chem"},{"issue":"6","key":"10.1016\/j.jpet.2026.104997_bib109","first-page":"641","article-title":"Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting","volume":"17","author":"Janssen","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"10.1016\/j.jpet.2026.104997_bib110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.tips.2023.04.003","article-title":"Recent advances in the development of therapeutic peptides","volume":"44","author":"Fetse","year":"2023","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib111","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1021\/acs.jmedchem.0c01536","article-title":"Tuning the biological activity of RGD peptides with halotryptophans","volume":"64","author":"Kemker","year":"2021","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104997_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71771-8","article-title":"Halogenation as a tool to tune antimicrobial activity of peptoids","volume":"10","author":"Molchanova","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2026.104997_bib113","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.biopha.2016.10.102","article-title":"Improved breast cancer cell-specific intracellular drug delivery and therapeutic efficacy by coupling decoration with cell penetrating peptide and SP90 peptide","volume":"84","author":"Fan","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jpet.2026.104997_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113050","article-title":"Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment","volume":"213","author":"Deng","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10.1016\/j.jpet.2026.104997_bib115","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/acs.bioconjchem.1c00319","article-title":"Targeted delivery of cabazitaxel using cyclic cell-penetrating peptide and biomarkers of extracellular matrix for prostate and breast cancer therapy","volume":"32","author":"Park","year":"2021","journal-title":"Bioconjug Chem"},{"issue":"5","key":"10.1016\/j.jpet.2026.104997_bib116","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.3390\/ijms24054646","article-title":"Transcytosable peptide-paclitaxel prodrug nanoparticle for targeted treatment of triple-negative breast cancer","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:18:15Z","timestamp":1793265495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022356526011973"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104997","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide\u2013drug conjugates in breast cancer therapy: Emerging targets, translational challenges, and optimization strategies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104997"}}